The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol

,, with oral lipoic acid,nselenomethionine, silymarin, and B complex capsulesnHighlight:IVnALA can reach much higher plasma levels than the oral form, with the oral capsulesnmaintaining levels in between IV infusionsnHighlight:ALA has multiple activities; forninstance, it is a powerful antioxidant and heavy metal chelatornHighlight:3 of its actions are relevant in this case: itsnanti-inflammatory activity, the effect on mitochondrial metabolism, and itsnepigenetic activitynHighlight:Unmitigated NF-κB activation can produce proliferation, angiogenesis, mutagenesis,nmetastasis, and chemo-radio resistance in malignant cells and leave them resistantnto apoptosisnHighlight:Unmitigated NF-κB activation can produce proliferation, angiogenesis, mutagenesis,nmetastasis, and chemo-radio resistance in malignant cells and leave them resistantnto apoptosisnHighlight:ALA inhibits NF-κBnHighlight:PDK phosphorylates and inhibits PDHC, regulating its activity. ALA inhibits PDK, andnby doing so it further increases PDHC activitynHighlight:Knockdown of PDHK restored pyruvate dehydrogenase (PDH) activity, revertednthe Warburg metabolic phenotype, decreased invasiveness, and inhibited xenograftntumor growth in nude micenHighlight:inhibition of the Warburg effect inncolon cancer cells was associated with decreased cancer cell xenograft growth innnude micenHighlight:BRAFV600E-induced senescence wasnaccompanied by simultaneous inhibition of PDHKnHighlight:It is also possible, according to Kaplon’s work, thatntumor cell senescence may also be promoted by ALA’s action on these enzymesnHighlight:ALA concerns its epigenetic activity. ALAncan inhibit histone deacetylase (HDAC) activity in human tumor cellsnHighlight:cancer is not only a geneticndisease but is also a metabolic diseasenHighlight:HCA was synergistic with ALA to reduce tumor growth innvitro and in vivon]]>

About Dr. Nathan Goodyear
About Dr. Nathan Goodyear

Dr. Nathan Goodyear, a medical doctor with years of experience in the field of integrative cancer care, has announced the launch of an online training program. This program, available on his new website, will provide individuals with access to video trainings led by Dr. Goodyear himself, covering a range of topics related to integrative cancer care. These trainings will include information on the latest research and techniques in the field, as well as guidance on how to incorporate these approaches into a patient’s overall cancer treatment plan. With this online program, Dr. Goodyear hopes to make his expertise and knowledge more widely accessible, and help more people understand the benefits of integrative cancer care.

READ MORE

Leave a Comment

Your email address will not be published. Required fields are marked *

Skip to content